Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.46 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.36 |
| ▸ | RARA | P10276 | 6/20 | 0.36 |
| ▸ | RARB | P10826 | 6/20 | 0.36 |
| ▸ | RARG | P13631 | 6/20 | 0.36 |
| ▸ | HNF4A | P41235 | 2/20 | 0.36 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.36 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 4/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12468551 | 0.80 | PTGS2 (0.40) | PTGS2PTGS1SSTR5ALOX5RARA | |
| SCHEMBL12465802 | 0.77 | RARA (0.56) | PTGS2PTGS1SSTR5RARARARB | |
| SCHEMBL15397116 | 0.76 | GNG2 (0.41) | PTGS2PTGS1RARARARBRARG | |
| SCHEMBL1550094 | 0.69 | CYP3A4 (0.59) | RARARARBRARGCYP26A1CYP26B1 | |
| SCHEMBL7154625 | 0.69 | HNF4A (0.49) | PTGS2PTGS1SSTR5RARARARB | |
| SCHEMBL7161473 | 0.68 | PTGS2 (0.67) | PTGS2PTGS1ALOX5 | |
| SCHEMBL12465699 | 0.68 | SSTR5 (0.33) | PTGS2PTGS1SSTR5 | |
| SCHEMBL4612116 | 0.68 | PTGS2 (0.74) | PTGS2PTGS1ALOX5 | |
| SCHEMBL1849394 | 0.67 | CES2 (0.56) | PTPN1 | |
| SCHEMBL7196169 | 0.66 | PTGS1 (0.42) | PTGS2PTGS1SSTR5RARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2670744-B1 | PYRROLE DERIVATIVES USED AS MODULATORS OF ALPHA7 NACHR | LUPIN LTD (IN) | 2015-05-27 | — | — | EP | disclosed |
| EP-2670744-A1 | PYRROLE DERIVATIVES USED AS MODULATORS OF ALPHA7 NACHR | Lupin Limited (IN) | 2013-12-11 | — | — | EP | disclosed |
| US-20130310419-A1 | PYRROLE DERIVATIVES USED AS MODULATORS OF ALPHA7 NACHR | LUPIN LIMITED (IN) | 2013-11-21 | — | — | US | disclosed |
| WO-2012104782-A1 | PYRROLE DERIVATIVES USED AS MODULATORS OF ALPHA7 NACHR | LUPIN LIMITED (IN) | 2012-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310419-A1 | PYRROLE DERIVATIVES USED AS MODULATORS OF ALPHA7 NACHR | CHRNA7, CHRNE, CHRNA5 | PTGS2 3625/4885PTGS1 3008/4885SSTR5 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.